MLN 2238 - Ixazomib

Based on 270 reference(s) in Google Scholar 9 10 270

Axon 2556

CAS [1072833-77-2]

MF C14H19BCl2N2O4
MW 361.03

  • Purity: 98%
  • Solubble in DMSO

MLN 2238

Description

Selective and reversible inhibitor of the β5 subunit sites of the 20S proteasome with antitumor activity in various malignancies. MLN 2238 exhibits improved pharmacodynamics and antitumor activity compared with bortezomib in various B-cell lymphoma models, due to a greater tumor to blood ratio of proteasome inhibition that ultimately translates into improved tumor pharmacodynamic response and antitumor activity in several tumor xenograft models. 

MLN 2238 is also available as the more stable citrate prodrug MLN 9708 (Axon 2557).

KEYWORDS: MLN 2238 | supplier | Proteasome inhibitor | Ixazomib | MLN2238 | CAS [1072833-77-2] | Ubiquitin | Proteasome 20S | Inhibitor | β5 subunit | B-cell lymphoma | FDA approved | MLN 9708

Order
Size Unit Price Stock
5 mg €85.00 In Stock
25 mg €295.00 In Stock
Special Offers
Size Unit Price Stock
2 x 5 mg €140.00 In Stock
Need more? Bulk Inquiry

The purity of Axon Ligands™ is confirmed by HPLC-MS, 1H-NMR and/or microanalysis. Analytical data are available upon request.

Caution: Axon Ligands™ are not fully tested. They are for research purposes only! Not for human consumption!

Please wait...